SR-18292 (C007B-272664)

InformationSR-18292 SR-18292 inhibits PGC-1α gluconeogenic activity and reduces co-activation of HNF4α by modulating the interaction between GCN5 and PGC-1α.TargetsPGC-1αIn vitroSR-18292 is a potent inhibitor of the gluconeogenic gene expression and glucose production in hepatocytes. It increases the interaction of PGC-1α with GCN5 and reduces co-activation of HNF4α by PGC-1α. SR-18292 suppresses HNF4α/PGC-1α gluconeogenic transcriptional function.In vivoSR-18292 reduces blood glucose, strongly increases hepatic insulin sensitivity and improves glucose homeostasis in dietary and genetic mouse models of type 2 diabetes. SR-18292 suppresses hepatic glucose production and increases liver insulin sensitivity in vivo. The liver is a major target of SR-18292 and probably accounts for a significant part of its anti-diabetic effects.Cell Research(from reference)Cell lines：U-2 OS cells overexpressing Ad-GCN5 Concentrations：10 μM Incubation Time：18 h.

Specifications and Purity: ≥98%

Molecular Formula: C23H30N2O2

Molecular Weight: 366.5

PubChem CID: 129896798

Isomeric SMILES: CC1=CC=C(C=C1)CN(CC(COC2=CC=CC3=C2C=CN3)O)C(C)(C)C

Related Documents: https://aladdin-for-icloud-store.oss-cn-hangzhou.aliyuncs.com/aladdinsci/pdp/sds/1/S414040-SCI_68fd9634188770510f6bf21469701153.pdf